(Q30312208)

16 June 2017

1 reference

title

Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials (English)

1 reference

16 June 2017

1 reference

Stephen H Caldwell

1

1 reference

16 June 2017

Charissa Chang

series ordinal

2

1 reference

16 June 2017

B Gail Macik

series ordinal

3

1 reference

16 June 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

16 June 2017

1 reference

16 June 2017

volume

39

1 reference

16 June 2017

issue

3

1 reference

16 June 2017

page(s)

592-598

1 reference

Pharmacokinetics and pharmacodynamics of recombinant factor VIIa

16 June 2017

cites work

1 reference

Early indicators of prognosis in fulminant hepatic failure

21 January 2018

1 reference

Coagulation defects in liver disease.

21 January 2018

1 reference

Outpatient liver biopsy: how safe is it?

21 January 2018

1 reference

Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution

21 January 2018

1 reference

Variation between centers in technique and guidelines for liver biopsy.

21 January 2018

1 reference

7 January 2021

Percutaneous liver biopsy: what is the current approach? Results of a questionnaire survey

1 reference

7 January 2021

Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000.

1 reference

7 January 2021

New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa

1 reference

7 January 2021

Effect of individual dietary fatty acids on postprandial activation of blood coagulation factor VII and fibrinolysis in healthy young men

1 reference

7 January 2021

Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantation

1 reference

7 January 2021

Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation

1 reference

7 January 2021

Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study

1 reference

7 January 2021

High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system.

1 reference

7 January 2021

Use and validation of selection criteria for liver transplantation in acute liver failure

1 reference

7 January 2021

Transection of the oesophagus for bleeding oesophageal varices

1 reference

7 January 2021

Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics

1 reference

7 January 2021

Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver?

1 reference

7 January 2021

Differentiation of autoimmune thrombocytopenia from thrombocytopenia associated with immune complex disease: systemic lupus erythematosus, hepatitis-cirrhosis, and HIV-1 infection by platelet and serum immunological measurements

1 reference

7 January 2021

Abnormal Fibrin Polymerization in Liver Disease

1 reference

7 January 2021

Disseminated intravascular coagulation in liver cirrhosis

1 reference

7 January 2021

Hematologic aspects of end-stage renal failure

1 reference

7 January 2021

Platelet function in chronic liver disease: relationship to disease severity

1 reference

7 January 2021

Bleeding after liver biopsy does not correlate with indices of peripheral coagulation

1 reference

7 January 2021

Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage

1 reference

7 January 2021

1 reference

7 January 2021

Guidelines on the use of liver biopsy in clinical practice

1 reference

7 January 2021

Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy

1 reference

7 January 2021

Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy

1 reference

7 January 2021

Coagulopathy of fulminant hepatic failure

1 reference

7 January 2021

Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats

1 reference

7 January 2021

Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices

1 reference

7 January 2021

Recombinant-activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices

1 reference

7 January 2021

Management of adult patients with ascites caused by cirrhosis

1 reference

7 January 2021

Invasive line placement in critically ill patients: do hemostatic defects matter?

1 reference

7 January 2021

Percutaneous cannulation of the internal jugular vein in patients with coagulopathies: an experience based on 1,000 attempts

1 reference

7 January 2021

rVIIa therapy to secure haemostasis during central line insertion in children with high-responding FVIII inhibitors

1 reference

7 January 2021

Use of recombinant factor VIIa to treat persistent bleeding following dental extractions in two cirrhotic patients

1 reference

7 January 2021

Use of activated recombinant human factor VII (rhFVIIa) for colonic polypectomies in patients with cirrhosis and coagulopathy

1 reference

7 January 2021

Intraoperative blood losses and transfusion requirements during adult liver transplantation remain difficult to predict.

1 reference

7 January 2021

Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII

1 reference

7 January 2021

Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study.

1 reference

7 January 2021

Pseudoprolongation of the Prothrombin Time During Treatment with Recombinant Factor VIIa for Bleeding in a Patient with a Spontaneous Factor VIII Inhibitor

1 reference

7 January 2021

Treating Thrombosis in the 21st Century

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.20123

1 reference

16 June 2017

1 reference